CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
85 hedge funds and large institutions have $127M invested in CASI Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 5 closing their positions.
2,598% more capital inflows, than outflows
Capital inflows: $34M | Capital outflows: $1.26M
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 16
16% more funds holding
Funds holding: 73 → 85 (+12)
4.54% more ownership
Funds ownership: 33.42% → 37.97% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.85M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$8.32M |
| 3 |
TLP
Tri Locum Partners
New York
|
+$4.21M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.55M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$1.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$336K |
| 2 |
Morgan Stanley
New York
|
-$144K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$133K |
| 4 |
Millennium Management
New York
|
-$124K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$100K |
CASI Hedge Fund Activity: Q1 2021 in Review
85 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2021, worth a combined $127M — up 4.2% from $122M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CASI positions and 5 closed out — a net gain of 13 holders — while 32 added to existing stakes and 16 trimmed.
The largest buyer was Federated Hermes, adding an estimated $8.85M. The largest seller was Northern Trust, cutting an estimated $336K.
- 85 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2021, up from 73 in Q4 2020.
- Funds reported $127M of CASI Pharmaceuticals stock for Q1 2021, up 4.2% quarter-over-quarter.
- 18 funds opened new CASI Pharmaceuticals positions in Q1 2021 and 5 closed out, a net change of +13 holders.
- The largest CASI Pharmaceuticals buyer in Q1 2021 was Federated Hermes, an estimated $8.85M added.
- The largest CASI Pharmaceuticals seller in Q1 2021 was Northern Trust, an estimated $336K sold.
Based on aggregated 13F filings for Q1 2021.